Navigation Links
Glenmark Announces the Discovery of a Novel Chemical Entity 'GRC 17536', a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
Date:8/31/2010

Glenmark Announces the Discovery of a Novel Chemical Entity 'GRC 17536', a... -- MUMBAI, India, August 31, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Glenmark Announces the Discovery of a Novel Chemical Entity 'GRC 17536', a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally

 

MUMBAI, India, August 31, 2010 /PRNewswire-FirstCall/ --

- With This Announcement, Glenmark has Clearly Reaffirmed its Position Globally as the Leader in the TRP Space

Glenmark Pharmaceuticals today announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting TRPA1 receptor antagonists for pain and respiratory disorders. TRPA1 belongs to Transient Receptor Potential (TRP) family of ion channels, which have generated a lot of interest as pain targets due to their distinguishing role in peripheral and/or central pain signal transmission.

Glenmark has selected a lead molecule named GRC 17536 which is currently finishing up Phase 1 enabling GLP studies. Preclinical studies have been completed and Glenmark plans to file the Phase 1 application in January 2011. This is another potential first-in-class molecule globally for Glenmark

Commenting on this discovery, Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals ltd mentioned " Both our earlier TRP molecules i.e. TRPV1 and TRPV3 resulted in outlicensing deals for the company. GRC 17536 which is a TRPA1 receptor antagonist is another potential first-in-class globally and we are encouraged by the results shown by the molecule in animal studies. GRC 17536 is highly selective even when compared with other TRPs and can be administered orally"

Glenmark is now positioned as one of the leading companies engaged in the discovery of novel TRP antagonists. Previously Glenmark has worked on TRPV1 and TRPV3 receptors and was able to successfully bring programs into clinical development. Both of these programs also resulted in out-licensing deals for Glenmark.

GRC 17536, which is Glenmark's lead is a highly potent (< 10nM) TRPA1 antagonist, which is highly selective (> 1000 fold over other TRPs) and orally available. It has proven highly efficacious in treating inflammatory and neuropathic pain in animal models compared to gold standard drugs. It reversed hyperalgesia in vivo models of Freund's complete adjuvant - induced inflammatory and chronic constriction injury (CCI) - induced neuropathic pain with an EC50 of less than 10 mg/kg. In addition, when tested in an in vivo model of asthma, it showed promising effect on airway inflammation, bronchoconstriction and cough. So far, the compound has showed good safety in the safety pharmacology and toxicology studies performed till date.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). The company has a significant presence in branded generics markets across emerging economies including India.

For further information, please contact: Jason D'Souza Glenmark, Mumbai, India Tel: +91-22-40189919 Email: media@glenmarkpharma.com
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
2. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
3. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
4. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
5. GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
6. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
7. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
8. Governor OMalley Announces State Grants Available For Maryland Bio Companies
9. Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey
10. Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO)
11. 3SBio Inc. Announces Unaudited Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):